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Abstract—Traumatic brain injury (TBI) releases a cascade of inﬂammatory cytokines. Vagal nerve
stimulation (VNS) and ghrelin have known anti-inﬂammatory effects; furthermore, ghrelin release is
stimulated by acetylcholine. We hypothesized VNS decreases post-TBI inﬂammation through a
ghrelin-mediated mechanism. TBI was created in ﬁve groups of mice: sham, TBI, TBI/ghrelin, TBI/
VNS, and TBI/VNS/ghrelin receptor antagonist (GRa). Serum and tissue ghrelin, and serum TNF-α
were measured. Ghrelin increased following VNS 2 h post-TBI compared to sham or TBI. At 6 h,
TBI and TBI/VNS/GRa had increased TNF-α compared to sham while TBI/VNS and TBI/ghrelin
had TNF-α level comparable to sham. The highest ghrelin was measured in stomach where TBI
decreased ghrelin in contrast to an increase by VNS. In conclusion, VNS increased serum ghrelin
and decreased TNF-α following TBI. This was abrogated with GRa. Our data suggests that ghrelin
plays an important role in the anti-inﬂammatory effects of VNS following TBI.
KEY WORDS: traumatic brain injury; inﬂammation; vagus nerve; ghrelin; neuroenteric axis.
INTRODUCTION
Traumatic brain injury (TBI) continues to be a
multibillion dollar healthcare epidemic, causing death,
long-term hospitalization, and prolonged disability [1].
Most current TBI therapies are targeted to prevent the
sequelae of intracranial hypertension, optimize oxygen-
ation, and tissue perfusion [2]. Recently, various clinical
and animal studies have highlighted the importance of
mitigating TBI-induced alterations in homeostasis to
improve outcomes [3]. A recent retrospective study has
shown that exposure to beta blockade during hospital-
ization following TBI decreases the risk of mortality
despite the fact that patients were older, had higher
injury severity scores, and had greater comorbidities [4].
What has yet to be elucidated, however, are the
molecular and physiologic mechanisms behind these
observed clinical effects. We, and others, have
postulated that preventing the post-TBI inﬂammatory
surge may prevent the systemic inﬂammatory response
syndrome, sepsis and multi-system organ failure [5, 6].
Recently, we have shown that electrical vagus nerve
stimulation (VNS) decreases post-TBI inﬂammation deter-
mined by lower levels of TNF-α and prevents intestinal
injury determined by histology and decreased intestinal
permeability [5]. Tracey et al. has shown that VNS, in a
mouse model of sepsis, decreases mortality and the surge
of inﬂammatory cytokines likely mediated through acetyl-
choline binding to macrophage nicotinic receptors [7].
The orexigenic hormone ghrelin, described in 1999,
has been shown to have several anti-inﬂammatory
properties in addition to its known effect on pituitary
regulation and food intake [8]. Wu et al. have shown
that intravenous ghrelin in septic mice decreases levels
of the pro-inﬂammatory cytokines IL-1 and IL-6 [9].
Furthermore, the ghrelin receptor has been localized to
the dorsal motor nucleus of the vagus in the brain
indicating that ghrelin may regulate or be regulated by
the vagus nerve [10]. Other evidence demonstrates that
acetylcholine increases serum ghrelin levels, further
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214implicating the involvement of the vagus nerve in
ghrelin regulation [11]. Whether VNS prevents inﬂam-
mation by a ghrelin mediated pathway is unknown. We
hypothesized that electric VNS decreases post-TBI
inﬂammatory cytokines through a ghrelin mediated
mechanism.
MATERIALS AND METHODS
Mouse TBI Model
Animal experiments, including anesthesia, TBI, and
recuperation, were approved through the university
Institutional Animal Care and Use Committee (Approval
#S08110). Male Balb/c mice (20–24 g) were obtained
from The Jackson Laboratory (Sacramento, CA, USA)
and placed under a 12-h light and dark cycle. A weight
drop TBI model, as previously described, was used to
cause a right-sided cerebral contusion [5, 12]. Brieﬂy,
animals were anesthetized with 3% inhaled isoﬂurane.
Each animal (n=8 in each group) was manually secured
and its head shaved with an electric clipper after which a
vertical incision was made over the cranium and using a
surgical drill, a burr hole, 4 mm in diameter, 1 mm
lateral, and 1 mm posterior to the bregma was created to
expose the dura mater. A 250-g metal rod was dropped
from a height of 2 cm onto the exposed dura mater. The
incision was closed with vet bond and buprenorphine
(100 μL) was injected subcutaneously for analgesia.
Food and water were provided ad libitum.A n i m a l sw e r e
sacriﬁced, between 11:00A.M. and 2:00P.M., following
cardiac puncture by cervical dislocation. In one arm,
surgical abdominal vagotomy was performed imme-
diately prior to vagal nerve stimulation and TBI
through an upper-midline laparotomy incision. The
gastroesophageal junction was identiﬁed and the
dorsal and ventral vagus nerve were visualized and
ligated on the distal esophagus with an Olympus
SZ61 stereomicroscope (Leeds Precision Instruments,
Minneapolis, MN, USA).
Vagal Nerve Stimulation
Following induction of general anesthesia with
inhaled isoﬂurane, a right cervical neck incision was
performed and the right cervical vagus nerve exposed
[5]. Vagal nerve stimulation was performed using a
VariStim III probe (Medtronic Xomed, Jacksonville, FL,
USA) at 2 mA for 10 min. The incision was closed with
interrupted silk sutures and the animal was immediately
subjected to TBI as previously described. Sham animals
underwent right cervical incision and exposure of the
vagus nerve but did not receive stimulation.
Ghrelin and Ghrelin Antagonist Administration
Animals in the ghrelin group (n=8) received two
doses of intraperitoneal (IP) ghrelin (10 μg) immediately
prior to and 1 h after TBI. The dosing and timing of
ghrelin administration was determined from previous
experiments showing that IP ghrelin has a rapid onset of
action and its response is potentiated by a second IP
injection within 4 h [13, 14]. Select animals received
6 mg/kg IP of a commercially available selective ghrelin
antagonist ([d-Lys-3]-GHRP-6; AnaSpec, San Jose, CA,
USA) before VNS.
Levels of Serum TNF-α and Ghrelin
Serum TNF-α levels were measured in sham or at
2, 4, and 6 h following TBI in all groups, using a
commercially available ELISA kit (R & D system,
Minneapolis, MN, USA). Values are reported as pico-
gram per milliliter. Active serum ghrelin levels were
measured in serum post-TBI in each group using a
commercially available ELISA kit (Linco Research, St.
Charles, MO, USA).
Tissue Levels of Ghrelin
Active tissue ghrelin levels were measured in
stomach, intestine, brain, lung, and liver 2 h post-TBI
in each group (n=6 animals in each group) using a
commercially available ELISA kit (Linco Research,
St. Charles, MO, USA). Protein was extracted by
homogenizing tissue in 500 μL of ice-cold tissue
protein extraction reagent containing 1% protease
inhibitor and 1%phosphataseinhibitor (PierceBiotechnol-
ogy, Rockford, IL, USA). Homogenates were centrifuged
at 10,000×g for 5 min. The supernatant was obtained and
stored at −70°C. Values are reported as picogram per
milliliter.
Statistical Analysis
Values are expressed as mean±standard error of the
mean. The statistical signiﬁcance among groups was
determined by t test or analysis of variance with
Bonferroni correction where appropriate, and a p value
<0.05 was considered statistically signiﬁcant.
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Levels of Serum TNF-α
Levels of serum TNF-α were measured by ELISA
in all groups with the highest levels observed in TBI at
6 h compared to sham (34.4±1.9 vs. 22.9±1.4 pg/ml; p<
0.001). VNS prevented the increase in TNF-α following
TBI reducing levels to that of sham (34.4±1.9 vs. 21.8±
1.0 pg/ml; p<0.03; Figs. 1 and 2). Likewise, exogenous
ghrelin also prevented the increase in TNF-α following
TBI reducing levels to that similar to sham and vagal
stimulation (34.4±1.9 vs. 24.0±1.5 pg/ml p<0.02;
Fig. 2). In contrast, in animals treated with a ghrelin
antagonist, VNS did not decrease serum TNF-α levels
which remained elevated 6 h post-TBI (34.4±1.9 vs.
34.9±2.9 pg/ml; p=NS; Fig. 2).
Serum Levels of Ghrelin
Serum levels of ghrelin were measured by ELISA
at 2, 4, and 6 h following TBI, TBI+VNS, and TBI+
VNS+vagotomy. Compared to baseline (656.7±
189 pg/ml), ghrelin levels in the TBI alone group
w e r eu n c h a n g e da t2h( 6 5 2 . 2 ± 7 3p g / m l ;p=NS) and
trended lower at 4 h (531.6±27 pg/ml; p= N S )a n d6h
(442±21 pg/ml; p=NS). Following VNS however,
ghrelin levels increased signiﬁcantly compared to
baseline and TBI at 2 h (1,200.0±162 pg/ml; p<
0.01) and 4 h (850.2±33 pg/ml; p=0.03) but
decreased to levels of sham and TBI alone at 6 h
(541.4±25 pg/ml; p=NS; Fig. 3). Animals undergoing
surgical vagotomy, prior to VNS and TBI, had ghrelin
levels similar to TBI alone at 2 h (578.3±107.3 pg/ml; p=
NS) and decreased compared to TBI+VNS (p=0.03).
Ghrelin levels remained comparable to TBI at 4 h but
decreased to levels similar to TBI and TBI+VNS at 6 h.
Tissue Levels of Ghrelin
Tissue levels of ghrelin were measured in sham, 2 h
post-TBI and 2 h post-TBI+VNS. Extracted protein
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Fig. 1. Levels of serum TNF-α 2, 4, and 6 h following TBI in all groups.
The highest mean levels were observed in TBI at 6 h compared to sham
(34.4±1.9 vs. 22.9±1.4 pg/ml; *p<0.03). VNS prevented the increase in
TNF-αfollowingTBIreducinglevelsto thatofsham(22.9±1.4vs.21 .8±
1.0 pg/ml, †p=NS).
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Fig. 2. Levels of TNF-α 6 h following TBI and exogenous ghrelin
(Gh). Gh prevented the increase in TNF-α following TBI (34.4±1.9 vs.
24.0±1.5 pg/ml; *p<0.02) reducing mean levels to that similar to
sham and vagal stimulation. (22.9±1.4 vs. 24.0±1.5 pg/ml; †p=
NS). Blocking the Gh receptor via a ghrelin antagonist ([d-Lys-3]-
GHRP-6) prevents the VNS decrease of serum TNF-α levels. The
addition of a ghrelin antagonist (GA) preceding VNS and TBI pr-
evented VNS induced reduction of mean serum TNF-α (34.4±1.9
vs. 34.9±2.9; pg/ml, p=NS).
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Fig. 3. Post-TBI mean serum Gh levels increase following VNS.
Compared to baseline (656.7±189 pg/ml), Gh levels in TBI were un-
changed at 2 h (652.2±73 pg/ml; p=NS), trended lower at 4 h (531.6±
27 pg/ml; p=NS) and at 6 h (442±21 pg/ml; p=NS). In VNS, Gh
levels increased signiﬁcantly compared to baseline and TBI at 2 h (-
1,200.0±162 pg/ml; *p<0.01) and 4 h (850.2±33 pg/ml; **p=0.03)
but decreased to levels of sham and TBI alone at 6 h (541.4±25 pg/ml;
p=NS). Gh levels did not increase in vagotomized animals that unde-
rwent VNS with levels similar to TBI alone at 2 h (578.3±107.3 pg/ml;
p=NS) and decreased compared to TBI+VNS (p=0.03).
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measured for ghrelin, of which stomach had the highest
levels of ghrelin followed by small intestine (Fig. 4).
Compared to sham, post-TBI stomach had 4,780±
232 pg/ml of ghrelin. Post-TBI ghrelin levels decreased
to 4,037±137 pg/ml compared to sham (p=0.05).
However, VNS increased ghrelin levels signiﬁcantly
compared to TBI and trended higher compared to sham
(5,223±414 pg/ml; p=0.04, p=0.06).
DISCUSSION
It is now well-established that increasing para-
sympathetic tone, through vagal nerve stimulation,
decreases inﬂammation in various models of physiologic
insult including cecal ligation and puncture, LPS
injection, severe burn injury and TBI [5, 15, 16]. Tracey
et al. has shown, in a murine sepsis model, that VNS
prior to endotoxin injection decreases serum TNF-α and
improves animal survival [17]. Current evidence
explaining these ﬁndings suggests that VNS increases
levels of synaptic acetylcholine which bind to α-7
muscuranic receptor of immune cells (i.e., macrophages)
and consequently decreases the release of TNF-α [18].
Vagotomized animals lose this effect and exhibit
elevated levels of TNF-α with aggravation of lethal
shock. Recently, we have shown that VNS prevents an
increase in TNF-α following TBI and prevents intestinal
injury as determined by improving histopathology and
decreasing intestinal permeability [5]. The mechanism of
these ﬁndings are unclear, and may well be similar to the
mechanism of preventing TNF-α release by macro-
phages as demonstrated by the Tracey group. However,
TBI has global and unique physiologic effects. These
systemic sequelae are complex and affect virtually every
organ including the cardiovascular, respiratory, gastro-
intestinal, and neuroendocrine systems [6, 19]. There are
several proposed etiologies behind these observations
including a post-TBI adrenergic surge, decreased sym-
pathetic tone, and a surge in inﬂammatory cytokines.
Several investigators have attempted to modulate the
response of neurogenic injury by varying medical
regimens attenuating sympathetic activity by beta block-
ade [4, 20]. In an early study, Walter et. al.[ 21] has
demonstrated that an early adrenergic blockade confers
improved survival and overall outcome in patients with
subarachnoid hemorrhage. Two recent, retrospective
studies in the trauma population have shown that
exposure to beta blockade, during hospitalization for
TBI, improve overall outcomes and decrease the risk of
mortality [4, 20]. These observations, coupled with
laboratory data, have lead several authors to demonstrate
that increasing parasympathetic tone, via electrical VNS,
prevents inﬂammation and organ dysfunction following
various injury models.
Beyond the anti-inﬂammatory effects, the vagus
nerve serves as the conduit for neuroenteric communi-
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Fig. 4. VNS stimulation signiﬁcantly increases stomach Gh levels 2 h following TBI. Tissue levels of Gh were measured in stomach, intestine, brain,
lung, and liver. Stomach had the highest levels of Gh followed by small intestine. Compared to sham stomach Gh levels (4,780±232 pg/ml), post-TBI
Gh levels decreased to 4,037±137 pg/ml (*p=0.05). However, VNS increased mean Gh levels signiﬁcantly compared TBI and trended higher
compared to sham (5,223±414 pg/ml; *p=0.04; †p=0.06).
217 Vagal Stimulation Increases Serum Ghrelincation where increased vagus nerve activity, both central
and peripheral, leads to increased gastrointestinal motil-
ity, increased pancreatic exocrine function and changes
in neuroendocrine proﬁles [22]. The hormone ghrelin,
predominantly produced in the stomach and small
bowel, has been shown to inﬂuence central vagus nerve
activity. Wu et al. has shown that exogenous ghrelin,
administered in a mouse model of endotoxemia, down-
regulates inﬂammatory cytokine TNF-α and IL-6 release
through activating the vagus nerve, suggesting that
ghrelin may link the central nervous and the immune
system [9]. Under this paradigm, ghrelin increases vagus
nerve activity which consequently increases acytelcho-
line and therefore decreases release of TNF-α from
macrophages and monocytes. Accordingly, our lab has
recently reported exogenous ghrelin prevents intestinal
injury and intestinal permeability following TBI [23].
However, the question of whether VNS, in and of itself,
actually changes tissue and serum levels of ghrelin needs
to be investigated.
The anti-inﬂammatory activity of ghrelin has only
recently been recognized. Current data suggests that
ghrelin binds to ghrelin receptors located on macro-
phages [24]. This action decreases phosphorylation of
NFκB and thereby decreases the transcription of
inﬂammatory cytokines such as TNF-α and IL-6. In
another study, Wu et al.[ 25] demonstrated that
exogenous ghrelin, given in septic mouse models,
prevented gut barrier dysfunction and reduced circu-
lating levels of HMGB-1, emphasizing the anti-
inﬂammatory actions of ghrelin. Additionally, Koch
et al.[ 26], in an analysis of critically ill patients,
demonstrated that higher endogenous ghrelin levels
detected early in the patients’ hospital course correlated
with increased survival. Given that vagus activity has
several effects on the gastrointestinal system, we postu-
lated that VNS increases serum ghrelin and the subsequent
increase in ghrelin was responsible, at least in part, to
decrease post-TBI inﬂammation.
As in our previous TBI studies, we report that VNS
decreased serum TNF-α following TBI. Exogenous
ghrelin also decreased post-TBI serum TNF-α with a
magnitude very similar to the observed TNF-α decrease
by VNS. Furthermore, pre-treating animals with a
ghrelin receptor antagonist abrogated the effects of
VNS indicating that the increase in ghrelin is important
in attenuating post-TBI inﬂammation. Taken together,
ghrelin levels, whether administered exogenously or
increased by VNS, decrease serum TNF-α following
TBI. Wu et al. showed that exogenous ghrelin decreased
macrophage derived TNF-α in sepsis. Their cytokine
measurements were taken 20 h after the initial septic
insult as the animals were receiving a continuous ghrelin
infusion [6]. In our data, serum ghrelin levels peak at 2 h
following VNS and trends downwards thereafter. Yet,
post-TBI serum TNF-α remains low at 6 h despite
ghrelin levels returning to baseline. This ﬁnding is not
entirely unexpected since this may reﬂect a delayed
effect a pulse of ghrelin may have on inﬂammatory
cytokine transcription and release. It is unknown how
long the anti-inﬂammatory effect of ghrelin lasts. A
longer time course would be needed to further elucidate
this question. Nevertheless, given these ﬁndings, the
anti-inﬂammatory effects of VNS may partly be medi-
ated by increased ghrelin release from the gastrointesti-
nal system, speciﬁcally the stomach. In this regard, we
have also shown that serum ghrelin levels increase
signiﬁcantly following VNS, where stomach tissue was
found to have the highest levels of ghrelin. These results
coincide with another study where free ghrelin release
from isolated rat stomach was increased by adding
acetylcholine [11]. Similarly, Hosoda et al.[ 27] have
shown that serum ghrelin levels acutely drop following
vagotomy in a mouse model and are only restored after
48 h of normal feeding. Interestingly, our data shows
higher levels of ghrelin in small intestine following
TBI when compared to sham and TBI+VNS. Even
though this ﬁnding was not statistically signiﬁcant, it
is possible that post-TBI-induced intestinal motility
dysfunction may have an effect on small bowel tissue
ghrelin levels. This would be an interesting area of
investigation. The exact mechanism explaining why
VNS releases ghrelin is yet unknown. Perhaps
acytelcholine, released from neuroenteric synapses
following VNS, causes increased expression and
excretion of ghrelin from gastrointestinal neuroendo-
crine cells similar to other hormones such as gastrin
and cholecystokinin. It is plausible that while exoge-
nous ghrelin may increase vagus nerve signaling,
other gastrointestinal hormones, such as leptin, may
serve to inhibit further vagus nerve activity. Indeed,
leptin has been shown to increase TNF-α and IL-6
release from macrophages and evidence exists show-
ing that leptin concentrations may be regulated by the
central nervous system [28–31]. Given our ﬁndings
and the current literature, gastrointestinal hormones
such as ghrelin seem to modulate cytokine release and
expression, however, the exact interplay between
parasympathetic tone, ghrelin regulation, and overall
inﬂammation needs further study.
218 Bansal, Ryu, Lopez, Allexan, Krzyzaniak, Eliceiri, Baird, and CoimbraIn summary, following TBI, TNF-α levels are
decreased with both electric vagus nerve stimulation and
exogenous ghrelin. VNS increases serum ghrelin which is
mostly derived from the stomach. Inhibiting the ghrelin
receptor prevents the anti-inﬂammatory effects of vagus
nervestimulationfollowingTBI.Ourdatasuggeststhatthe
release of ghrelin plays an important role in the anti-
inﬂammatory effects of VNS following TBI.
Limitations
It is important to recognize that ghrelin, like other
hormones, ﬂuctuates according to feedings and circadian
cycles.Inordertolimitvariationssecondarytotimeofday,
we measured all baseline ghrelin levels between 8:00 and
11:00A.M.andsacriﬁcedallanimalsbetween11:00A.M.and
2:00P.M. We did not account for ghrelin variation secon-
darytofoodintake.Itispossible,thatpost-TBIanimalsdid
not have the same volume of oral consumption following
injury altering ghrelin levels. A more formal study
examining the effects of TBI, enteral feeds, time of day,
and ghrelin levels would be an important future study.
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